echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Simplified licensing path for biosimilar drugs in the UK may become a new global regulatory trend

    Simplified licensing path for biosimilar drugs in the UK may become a new global regulatory trend

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    The British Medicines and Healthcare Products Regulatory Agency (MHRA) has proposed a simplified licensing approach for biosimilars, making the UK a world leader in the regulation of biosimilars.

    The MHRA formulated a plan to simplify the licensing of biosimilars last year.


    The plan usually does not require comparison of effectiveness data and will consider the exchange of approved biosimilars with reference products for all indications.


    Mark Samuels, head of the British Generic Drug Manufacturers Association and the affiliated British Biosimilars Association, commented, "This plan is very popular, and all of our manufacturers want to see the start of this plan.


    In addition, he believes, “Once the MHRA launches this program, the UK will become a world leader — a world leader with biosimilar modernization regulations.


    Christian Schneider, interim chief scientific officer of MHRA, said that the decision to no longer require confirmatory efficacy trials was brought about by the "excellent drug characterization" that is now possible.


    Schneider said, "We are studying responses to feedback," and MHRA acknowledged that the implementation of the new approach has been delayed due to COVID-19 activities.


    The EU and the U.


    Angela McFarlane, senior director of market development for the UK and Ireland of IQVIA, agreed with MHRA’s plan, “We can see that the UK is a global leader in rapidly approving new biosimilar drugs”, but “the biggest problem is that the US and the EU will follow suit.


    She said, “I think the European Medicines Agency (EMA) and the US FDA will pay close attention to the impact of the MHRA policy.


    Regardless of the proposed new approach, MacFarlane pointed out that the United Kingdom has “leading the European Union (France, Germany, Italy, and Spain) in the adoption of biosimilar drugs.







    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.